These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 11299844)

  • 1. Goserelin (Zoladex) or orchiectomy in metastatic prostate cancer? A quality of life and cost-effectiveness analysis.
    Nygård R; Norum J; Due J
    Anticancer Res; 2001; 21(1B):781-8. PubMed ID: 11299844
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Androgen level variations, clinical response to LHRH agonists and changes in the quality of life subscales in metastatic prostate cancer--speculations about possible role of the monoamine system.
    Popov I; Jelić S; Radosavljević D; Nikolić-Tomasević Z
    Neoplasma; 1997; 44(5):308-13. PubMed ID: 9473791
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Cost-utility analysis of androgen ablation therapy in metastatic prostate cancer].
    Fujikawa K; Awakura Y; Okabe T; Watanabe R; Nishimura S
    Nihon Hinyokika Gakkai Zasshi; 2003 May; 94(4):503-11; discussion 511-2. PubMed ID: 12795165
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effective models for flutamide for prostate carcinoma patients: are they helpful to policy makers?
    Bennett CL; Matchar D; McCrory D; McLeod DG; Crawford ED; Hillner BE
    Cancer; 1996 May; 77(9):1854-61. PubMed ID: 8646685
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relative effectiveness and cost-effectiveness of methods of androgen suppression in the treatment of advanced prostate cancer.
    Seidenfeld J; Samson DJ; Aronson N; Albertson PC; Bayoumi AM; Bennett C; Brown A; Garber A; Gere M; Hasselblad V; Wilt T; Ziegler K
    Evid Rep Technol Assess (Summ); 1999 May; (4):i-x, 1-246, I1-36, passim. PubMed ID: 11098244
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patient treatment preference in metastatic prostate cancer.
    Creagh T
    Ir Med J; 1996; 89(1):12. PubMed ID: 8984072
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term hormone therapy and radiation is cost-effective for patients with locally advanced prostate carcinoma.
    Konski A; Watkins-Bruner D; Brereton H; Feigenberg S; Hanks G
    Cancer; 2006 Jan; 106(1):51-7. PubMed ID: 16323171
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness analysis of LHRH agonists in the treatment of metastatic prostate cancer in Italy.
    Iannazzo S; Pradelli L; Carsi M; Perachino M
    Value Health; 2011 Jan; 14(1):80-9. PubMed ID: 21211489
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intermittent androgen suppression for locally advanced and metastatic prostate cancer: preliminary report of a prospective multicenter study.
    Sato N; Akakura K; Isaka S; Nakatsu H; Tanaka M; Ito H; Masai M;
    Urology; 2004 Aug; 64(2):341-5. PubMed ID: 15302491
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advanced prostate cancer. The role of high priced hormone therapy.
    Nicol DL; Heathcote PS; Kateley GD; Lloyd S
    Med J Aust; 1993 Jul; 159(1):16-9. PubMed ID: 8316105
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE).
    Kawakami J; Cowan JE; Elkin EP; Latini DM; DuChane J; Carroll PR;
    Cancer; 2006 Apr; 106(8):1708-14. PubMed ID: 16544313
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Androgen deprivation in men with prostate cancer is associated with an increased rate of bone loss.
    Preston DM; Torréns JI; Harding P; Howard RS; Duncan WE; McLeod DG
    Prostate Cancer Prostatic Dis; 2002; 5(4):304-10. PubMed ID: 12627216
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of androgen suppression therapies in advanced prostate cancer.
    Bayoumi AM; Brown AD; Garber AM
    J Natl Cancer Inst; 2000 Nov; 92(21):1731-9. PubMed ID: 11058616
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endocrine treatment of prostate cancer.
    Tammela T
    J Steroid Biochem Mol Biol; 2004 Nov; 92(4):287-95. PubMed ID: 15663992
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Economical data and advanced prostate carcinoma: do we need new guidelines for decision making?
    Rohde V; Wellmann A; Fogt F; Weidner W; Katalinic A
    Oncol Rep; 2002; 9(6):1185-8. PubMed ID: 12375016
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Eliciting patient preferences for hormonal therapy options in the treatment of metastatic prostate cancer.
    Lloyd A; Penson D; Dewilde S; Kleinman L
    Prostate Cancer Prostatic Dis; 2008; 11(2):153-9. PubMed ID: 17637761
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcomes of maximal androgen blockade in prostate cancer patients at a health area with type 2 reference hospital. Part 2. Quality of life: application of EORTC QLQ-PR25 instrument and global results. Quality-of-life adjusted survival. Pharmaceutical expenses and cost-utility.
    Guerra NA
    Arch Esp Urol; 2009 Sep; 62(7):543-70. PubMed ID: 19815968
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomised crossover trial to assess the tolerability of LHRH analogue administration.
    Williams G; Lindsay S; Bowsher WG
    Prostate Cancer Prostatic Dis; 2003; 6(2):187-9. PubMed ID: 12806381
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quality of life in goserelin-treated versus cyclophosphamide + methotrexate + fluorouracil-treated premenopausal and perimenopausal patients with node-positive, early breast cancer: the Zoladex Early Breast Cancer Research Association Trialists Group.
    de Haes H; Olschewski M; Kaufmann M; Schumacher M; Jonat W; Sauerbrei W;
    J Clin Oncol; 2003 Dec; 21(24):4510-6. PubMed ID: 14610048
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A cost-outcome analysis of long-term adjuvant goserelin in addition to radiotherapy for locally advanced prostate cancer.
    Samant RS; Dunscombe PB; Roberts GH
    Urol Oncol; 2003; 21(3):171-7. PubMed ID: 12810202
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.